{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:45Z","timestamp":1791357465316,"version":"4.3.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This controlled, randomized study investigated the hypothesis that the combined use of pregabalin plus paroxetine for fibromyalgia management would be associated with comparable Somatic Symptoms Scale\u20108 (<jats:styled-content style=\"fixed-case\">SSS<\/jats:styled-content>\u20108) and Center for Epidemiological Studies Depression Scale (<jats:styled-content style=\"fixed-case\">CESDS<\/jats:styled-content>) scores, but higher tolerability than the combined use of pregabalin plus either amitriptyline or venlafaxine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After institutional ethics committee approval, 75 female subjects diagnosed with fibromyalgia and in receipt of pregabalin (75 mg\/day) were randomly allocated to concurrently receive amitriptyline (25 mg\/day; <jats:italic>n<\/jats:italic> = 24), venlafaxine (75 mg\/day; <jats:italic>n<\/jats:italic> = 25), or paroxetine (25 mg\/day; <jats:italic>n<\/jats:italic> = 26). All patients were assessed bimonthly for 6 consecutive months for changes in <jats:styled-content style=\"fixed-case\">SSS<\/jats:styled-content>\u20108 and <jats:styled-content style=\"fixed-case\">CESDS<\/jats:styled-content> scores, life satisfaction, mood, sleep quality, fatigue, medication tolerability, and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with pregabalin plus amitriptyline or venlafaxine, the combined use of pregabalin plus paroxetine in fibromyalgia patients resulted in significantly lower <jats:styled-content style=\"fixed-case\">SSS<\/jats:styled-content>\u20108 and <jats:styled-content style=\"fixed-case\">CESDS<\/jats:styled-content> scores from 18 (<jats:italic>P<\/jats:italic> &lt; 0.05) and 10 weeks (<jats:italic>P<\/jats:italic> &lt; 0.001) after the initiation of study medications, respectively; higher medication tolerability (<jats:italic>P<\/jats:italic> &lt; 0.001); improved life satisfaction, mood, and sleep quality at most observation times (<jats:italic>P<\/jats:italic> &lt; 0.05); and fewer instances of dry mouth and elevated blood pressure (<jats:italic>P<\/jats:italic> &lt; 0.02). Medication termination due to poor tolerability was observed most frequently in the venlafaxine group (<jats:italic>P<\/jats:italic> &lt; 0.05), while drowsiness, dizziness, blurred vision, abnormal taste, hunger, hallucination, urination problems, and sexual dysfunction were observed most frequently in the amitriptyline group (<jats:italic>P<\/jats:italic> &lt; 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combined use of pregabalin plus paroxetine offers an effective method with increased tolerability to reduce the somatic and depressive symptoms of fibromyalgia and to enhance the quality of life in affected individuals.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12409","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T14:13:32Z","timestamp":1455977612000},"page":"32-40","source":"Crossref","is-referenced-by-count":19,"title":["Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study"],"prefix":"10.1111","volume":"17","author":[{"given":"Eiad A.","family":"Ramzy","sequence":"first","affiliation":[{"name":"Pain Clinic Department of Anaesthesia and Surgical Intensive Care Mansoura University Mansoura Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2008.00188.x"},{"key":"e_1_2_6_3_1","first-page":"690","article-title":"Fibromylagia","volume":"42","author":"Guymer E","year":"2013","journal-title":"Aust Fam Physician."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/08952841.2013.816221"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-012-1174-0"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_6_8_1","first-page":"CD008242","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","volume":"12","author":"Moore RA","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/1745017901309010120"},{"key":"e_1_2_6_10_1","first-page":"CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome","volume":"1","author":"H\u00e4user W","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12009"},{"key":"e_1_2_6_12_1","first-page":"33","article-title":"Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin or pregabalin","volume":"28","author":"Kim SC","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835a5d2e"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.21951"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.12179"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161206775193253"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1047343"},{"key":"e_1_2_6_18_1","first-page":"CD001980","article-title":"Mind and body therapy for fibromyalgia","volume":"4","author":"Theadom A","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2012.10.004"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.06.006"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(99)90008-5"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-013-0358-3"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01089-0"},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/2327-6924.12137","article-title":"The efficacy and tolerability of SSRI\/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review","volume":"27","author":"Handley AP","year":"2014","journal-title":"J Am Assoc Nurse Pract."},{"key":"e_1_2_6_25_1","first-page":"216","article-title":"Fluoxetine: a five years review","volume":"15","author":"Stokes PE","year":"1993","journal-title":"Clin Ther."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D112"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(98)71375-1"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12216"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu169"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1046841"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12409","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:22:43Z","timestamp":1695478963000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/papr.12409"],"URL":"https:\/\/doi.org\/10.1111\/papr.12409","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,19]]}}}